Entering text into the input field will update the search result below

Alnylam Pharma is said to be a potential target for Novartis - Bloomberg

Nov. 18, 2021 7:19 AM ETAlnylam Pharmaceuticals, Inc. (ALNY)NVS, NVO, REGN, NTLABy: Joshua Fineman, SA News Editor10 Comments

Novartis Pharmaceuticals Canada Inc. head office building in Dorval, Quebec, Canada.

JHVEPhoto/iStock Editorial via Getty Images

  • Alnylam Pharmaceuticals (NASDAQ:ALNY) may be a potential target for Novartis (NYSE:NVS) as investor push for the drugmaker to make an acquisition and use its cash. Alnylam rose 4.2% in premarket trading.
  • Alnylam, with a market cap of more

Recommended For You

Comments (10)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

ALNY has rapidly growing revenues, a great RNAi platform for drug development and great data on a potentially game changing therapy for hypertension. Plus NVS will save billions by not having to pay inclisiran royalties to ALNY. Impending buyout may explain Alnylam CEO’s John Maraganore surprising retirement plans. I sense there may be something to this.
haa haa just another rumor and bust!
If Novartis were economically savvy they'd go for VRTX instead. Next year's economic bust will be all about having US dollars or not. Not much use adding an EPS negative company to their assets.
stevevai1983 profile picture
@chrloe VRTX is too expensive for a buy out. You must prepare something like 70B.
@stevevai1983 your math is way way way way off. $70 billion would be around $600 per share. Nobody is talking anything in that price range.
@stevevai1983 sorry, thought you were talking about ALNY.
ALNY would be another bad acquisition for Novartis. Translation: they might actually do it to fail again.
@settembrini007 Bad because they have best in class platform technology? Or because every drug they try and launch smashes clinical expectations?
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.